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Abstract
Background
There is controversy about the effect of Helicobacter pylori (H. pylori) eradication on the
prevention of metachronous gastric cancer after endoscopic resection (ER).
Aims
The aim of this study was to systematically evaluate the effect of H. pylori eradication on the
prevention of metachronous gastric lesions after ER of gastric neoplasms.
Methods
We performed a systematic search of PubMed, EMBASE, the Cochrane Library, and MED-
LINE that encompassed studies through April 2014. Our meta-analysis consisted of 10
studies, which included 5881 patients who underwent ER of gastric neoplasms.
Results
When we compared the incidence of metachronous lesions between H. pylori-eradicated
and non-eradicated groups, H. pylori eradication significantly lowered the risk of metachro-
nous lesions after ER of gastric neoplasms (five studies, OR = 0.392, 95% CI 0.259 –
0.593, P < 0.001). When we compared H. pylori-eradicated and persistent groups, again,
H. pylori eradication significantly lowered the incidence of metachronous lesions after ER of
gastric neoplasms (six studies, OR = 0.468, 95% CI 0.326 – 0.673, P < 0.001). There was
no obvious heterogeneity across the analyzed studies.
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Conclusions
This meta-analysis suggests a preventive role for H. pylori eradication for metachronous
gastric lesions after ER of gastric neoplasms. Thus, H. pylori eradication should be consid-
ered if H. pylori infection is confirmed during ER.
Introduction
The incidence of early gastric cancer (EGC) has been increasing as screening upper endoscopy
has become widely available in Korea. The prognosis of EGC is quite favorable, with a 5 year
survival rate> 95% [1]. Therefore, endoscopic resection (ER) has been a standard treatment
for select cases of EGC in Korea. ER has many advantages, such as preservation of the stomach,
quality of life, and reduced health costs. However, risk of metachronous gastric cancer in the
remnant stomach after ER is higher than after gastrectomy [2]. The incidence of metachronous
gastric cancer within 3–5 years after ER is 2.7–14.0% [3,4]. Therefore, scheduled endoscopic
surveillance has been recommended to detect metachronous lesions after ER of EGC.
Helicobacter pylori (H. pylori) infection is closely related to progression to gastric dysplasia
or cancer. In 1994, the International Agency for Research on Cancer (IARC), a subdivision of
the World Health Organization (WHO), defined H. pylori as a group I carcinogen for gastric
carcinoma [5]. However, the exact role of H. pylori infection in development of metachronous
gastric lesions after ER has not been clearly elucidated. Fukase et al. reported that eradication
ofH. pylori after ER of EGC reduced the incidence of metachronous gastric cancer (odds ratio
(OR) 0.353, 95% CI 0.161–0.775, P = 0.009), and recommended that prophylactic eradication
should be pursued after ER [6]. However, Choi et al. showed that the incidence of metachro-
nous cancer did not differ significantly between H. pylori-eradicated and control groups. This
study enrolled 901 patients, who underwent ER for gastric dysplasia and cancer [7]. Thus, here
lies the controversy about the effect ofH. pylori eradication on prevention of metachronous
gastric cancer after ER. Therefore, we aimed to systematically evaluate the effect of H. pylori
eradication on prevention of metachronous gastric lesions after ER of gastric neoplasms.
Methods
Meta-analysis inclusion criteria
All relevant randomized controlled trials (RCTs) and retrospective cohort studies that com-
pared the effects of H. pylori eradication on prevention of metachronous gastric lesions after
ER of EGC were eligible for inclusion in our analysis.
Identification of appropriate studies
PubMed (1966 to April 2014), Cochrane Library (1997 to April 2014), MEDLINE (1966 to
April 2014), and EMBASE (1985 to April 2014) databases were queried during our computer-
aided search. Database searches used the following terms:Helicobacter pylori, H. pylori, meta-
chronous, second, recur, gastric dysplasia, neoplasm, and gastric cancer. We also searched ref-
erences manually in order to not miss relevant articles. Two reviewers (DH Jung and J-H Kim)
searched the databases independently. The primary outcome measure was the incidence of
metachronous gastric lesions after H. pylori eradication.
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Study selection
Titles and abstracts were screened by two reviewers, and studies were chosen for meta-analysis
if they were relevant. Language restrictions were not considered. If there was a disagreement, it
was resolved by simultaneous review.
Data extraction and quality assessment
Reviewers used standardized data extraction forms. Extracted data included baseline patient
and tumor characteristics, status of H. pylori infection and eradication, duration of follow-up,
and primary outcome measures reported by the authors. All obtained data were compared in
order to minimize error.
Measures of treatment effect
We compared the incidence of metachronous gastric neoplasms after ER of gastric neoplasms
betweenH. pylori-eradicated and non-eradicated groups. We also compared the incidence of
metachronous gastric neoplasms after ER of gastric neoplasms betweenH. pylori-eradicated and
persistent groups. The results of each study were reported as a risk ratio (RR) betweenH. pylori-
eradicated and non-eradicated or persistent groups, with a 95% confidence interval (CI).
Assessment of heterogeneity
Statistical heterogeneity among trials was assessed with χ2 and I2 tests. The I2 test measures the
percentage of variability between studies caused by heterogeneity but not chance. As values
from the I2 test increase, heterogeneity increases. Data were pooled according to the fixed-
effects and random-effects models.
Statistical analysis
The Begg’s funnel plot and Egger’s test were used to evaluate publication bias. P< 0.05 sug-
gested a significant publication bias. Data was analyzed using CMA ver. 2.0 software (Compre-
hensive Meta-Analysis, Englewood, NJ, USA). Weights were assigned to individual studies
based on the inverse of the variance. We used the PRISMA checklist (S1 PRISMA Checklist).
Results
Study inclusion
Our literature search yielded a total of 10 studies associated withH. pylori eradication and
metachronous gastric lesions that were included in the final analysis. Fig 1 shows the search
process that resulted in the final selection of eligible studies. Of the 1590 studies identified
through our search strategy, 1575 studies were excluded after review of titles and abstracts. The
15 articles that were potentially relevant were reviewed carefully. Of these, three studies were
excluded because they did not explore H. pylori [8–10], and one study was excluded due to an
insufficient description of metachronous gastric cancer [11]. The last study was excluded be-
cause it focused on patients with dysplasia [12].
Heterogeneity
There was no heterogeneity for the primary outcome between H. pylori-eradicated and non-
eradicated or persistent groups. There was no significant heterogeneity betweenH. pylori-
eradicated and non-eradicated groups (χ2 = 3.11, P = 0.539, and I2 = 0). Similarly, there was no
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significant heterogeneity between H. pylori-eradicated and persistent groups (χ2 = 2.05,
P = 0.842, and I2 = 0).
Effect of H. pylori eradication on prevention of metachronous lesions
after ER
Ten studies, which included 5881 patients, compared the effect ofH. pylori eradication on pre-
vention of metachronous lesions after ER of gastric neoplasm (Table 1). Among these, five
studies compared the incidence of metachronous lesions between H. pylori-eradicated and
non-eradicated groups [6,7,13–15]. Six studies compared the incidence of metachronous le-
sions between H. pylori-eradicated and persistent groups [14,16–20]. One study compared the
Fig 1. Flow chart for determining study inclusion .
doi:10.1371/journal.pone.0124725.g001
Table 1. Characteristics of studies that evaluated the effect of Helicobacter. pylori eradication on the prevention of metachronous gastric lesions
after endoscopic resection of gastric neoplasm.
Study
ID
Authors Year Ethnicity Sample size (No receiving
H. pylori eradication therapy)
Participant Metachronous
Recurrence
H. pylori Infection
status (%)
1 Uemura et al.
[15]
1997 Japanese 132 (67) EGC EGC 100
2 Nakagawa
et al.[13]
2006 Japanese 2825 (2469) EGC EGC 100
3 Fukase et al.[6] 2008 Japanese 505 (250) EGC EGC 100
4 Shiotani et al.
[16]
2008 Japanese 91 (0) EGC EGC 91.0
5 Maehata et al.
[18]
2012 Japanese 268 (0) EGC EGC 100
6 Choi et al.[7] 2013 Korean 880 (441) Gastric dysplasia
or EGC
Gastric dysplasia or
EGC
100
7 Seo et al.[17] 2013 Korean 74 (0) EGC EGC 100
8 Kim et al.[14] 2014 Korean 156 (88) EGC EGC 41.7
9 Bae et al.[19] 2014 Korean 667 (N/A) EGC EGC 66.2
10 Kwon et al.[20] 2014 Korean 283 (0) EGC Gastric dysplasia or
EGC
69.0
H. pylori, Helicobacter pylori
EGC, early gastric cancer
doi:10.1371/journal.pone.0124725.t001
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incidence of metachronous lesions between H. pylori-eradicated and non-eradicated or persis-
tent groups [14]. On the whole, compared with the H. pylori non-eradicated group, results
showed that H. pylori eradication was significantly helpful in preventing metachronous lesions
after ER of gastric neoplasms (OR = 0.392, 95% CI 0.259–0.593, P< 0.001) (Fig 2). When we
compared H. pylori-eradicated and persistent groups, H. pylori eradication significantly lower
the incidence of metachronous lesions after ER of gastric neoplasms (OR = 0.468, 95% CI
0.326–0.673, P< 0.001) (Fig 3). According to the Begg’s and Egger’s tests, there was no appar-
ent publication bias on the effect of H. pylori eradication for prevention of metachronous le-
sions after ER between H. pylori-eradicated and non-eradicated or persistent groups (Egger’s
test, P = 0.090 or 0.926, funnel plot, Fig 4).
Sensitivity analysis
A sensitivity analysis showed that the results of our meta-analysis could not be obviously influ-
enced by removing any one study (Fig 5).
Discussion
The effect of H. pylori eradication on the prevention of metachronous lesions after ER is still
controversial. Thus, it may be useful to combine the results of similar published studies to ar-
rive at a meaningful conclusion. As far as we know, this is the first meta-analysis to evaluate
the association between H. pylori eradication and the incidence of metachronous lesions. Based
Fig 2. Forest plot showing comparisons for the effect ofHelicobacter pylori eradication on
metachronous gastric lesions after endoscopic resection betweenHelicobacter pylori-eradicated and
non-eradicated groups.
doi:10.1371/journal.pone.0124725.g002
Fig 3. Forest plot showing comparisons for the effect ofHelicobacter pylori eradication on
metachronous gastric lesions after endoscopic resection betweenHelicobacter pylori-eradicated and
persistent groups.
doi:10.1371/journal.pone.0124725.g003
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on our findings, H. pylori eradication would be helpful for prevention of metachronous lesions
after ER.
Nowadays, ER is widely used for local treatment of a gastric neoplasm. In Korea, the num-
ber of patients who have undergone ER for gastric neoplasm has increased annually because of
the popularity of screening endoscopy [21]. TheH. pylori infection rate in patients undergoing
ER varies widely: 41.7–91.0% [14,16,19]. Our analysis suggests a preventive effect ofH. pylori
eradication since H. pylori eradication lowered the incidence of metachronous lesions after ER
(OR = 0.392, 95% CI 0.259–0.593, P< 0.001). However, patients persistently infected after re-
ceiving H. pylori treatment were included in these groups. The study by Choi et al. showed the
eradication rate of H. pylori after ER of gastric neoplasms [7]. PersistentH. pylori infection was
Fig 4. Publication bias plot for the effect of Helicobacter pylori eradication onmetachronous gastric
lesions after endoscopic resection. (A) comparison betweenHelicobacter pylori-eradicated and non-
eradicated groups; (B) comparison between Helicobacter pylori-eradicated and persistent groups.
doi:10.1371/journal.pone.0124725.g004
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found in 80 of 439 (18.2%) patients who received H. pylori treatment and in 373 of 441 (84.6%)
patients who did not receive H. pylori treatment. We compared the effect ofH. pylori treatment
between H. pylori-eradicated and persistent groups. SuccessfulH. pylori eradication was associ-
ated with a significant decrease in the incidence of metachronous lesions after ER (OR = 0.468,
95% CI 0.326–0.673, P< 0.001). This means that H. pylori eradication has a protective effect
for the development of metachronous lesions. And, successful eradication ofH. pylori is very
important for the prevention of metachronous lesions after ER of a gastric neoplasm.
A large, prospective, randomized study in China reported that the incidence of gastric can-
cer was similar between patients receiving H. pylori eradication treatment and those receiving
placebo. Subgroup analysis revealed that H. pylori eradication significantly inhibited develop-
ment of gastric cancer in patients without a precancerous lesion [22]. However, several reports
have shown thatH. pylori eradication decreases the incidence of gastric cancer in high-risk pa-
tients as well [23,24]. Bae et al. reported that H. pylori eradication prevents development of
metachronous lesions despite the presence of severe atrophy and intestinal metaplasia (IM) in
the mucosal background [19].
Metachronous gastric cancer can develop after ER. Therefore, evaluating the risk factors as-
sociated with metachronous gastric cancer is important. Kwon et al. showed that old age and
persistent H. pylori infection were independently significant risk factors for development of
metachronous gastric cancer after ER of EGC [20]. Hanaoka et al. reported that extensive atro-
phic fundic gastritis diagnosed by autofluorescence imaging is a significant predictor for devel-
opment of metachronous gastric cancer after H. pylori eradication [25]. According to Correa’s
hypothesis, atrophic gastritis and IM caused byH. pylori infection are closely associated with
the development of gastric cancer [26]. A meta-analysis of 12 studies inferred that H. pylori
Fig 5. Sensitive analysis for the effect of Helicobacter pylori eradication onmetachronous gastric
lesions after endoscopic resection. (A) comparison betweenHelicobacter pylori-eradicated and non-
eradicated groups; (B) comparison between Helicobacter pylori-eradicated and persistent groups.
doi:10.1371/journal.pone.0124725.g005
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eradication significantly improved atrophic gastritis [27]. We cannot interrupt age-related
atrophic changes in gastric mucosa. Thus,H. pylori eradication may be a very effective inter-
vention strategy for promoting regression of metachronous lesions after ER.
Metachronous gastric cancers are found more frequently in patients following ER than in
the gastrectomized stomach. It is caused naturally by the remnant stomach, which is preserved
after ER. In addition, the surrounding non-tumorous mucosa may be at high risk of developing
metachronous gastric lesions because it used to share the environment with gastric cancer [28].
Therefore, eradication ofH. pylori should be recommended to promote regression of back-
ground mucosa in patients after ER of a gastric neoplasm.
Our study has some limitations. First, the ethnicity of study participants included in this
meta-analysis was Korean and Japanese. The incidence of gastric cancer andH. pylori infection
in Eastern Asia is higher than in other areas of the world. And, ER of gastric neoplasm is per-
formed routinely in Korea and Japan [29–31]. Therefore, reports of an association between
H. pylori eradication and metachronous recurrence after ER might be published mostly in
Korea and Japan.
Secondly, our results did not segregate dysplasia and cancer. However, dysplasia was a pre-
cancerous lesion as Correa’s hypothesis [26]. Therefore, to elucidate the effect ofH. pylori erad-
ication on prevention of metachronous lesions after ER is significant in patients with dysplasia
or cancer.
In conclusion, the incidence of metachronous gastric cancer was higher in patients with
persistent H. pylori infection than in those whose H. pylori infection was eradicated. And,
eradication of H. pylori was helpful in decreasing the development of metachronous gastric
cancer. Thus, eradication of H. pylori should be recommended if H. pylori infection is con-
firmed after ER.
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